Presently, the Japanese Ministry of Health has approved the use of a thyrotropin-releasing hormone mimetic agent (taltirelin hydrate) for the treatment of SCA, but the use of this agent has not been approved in other countries (Ashizawa et al., 2018). Here, TRH is linked to autosomal dominant cerebellar ataxia.